Astrup (NN8022-1807) 2009

NCT00422058

1 Treatments

Studied treatment  4 liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg daily)

Control treatment  placebo

Concomittant treatments  -

Age (years)  -

female gender (%)  -

2 Patients

Patients  obese individuals without type 2 diabetes

Inclusion criteria  18-65 years of age, body mass index 30-40 kg/m2

Exclusion criteria  -

weight (kg)  -

BMI (kg/m2)  -

Diabetes mellitus (%)  -

3 Methods

Blinding  double blind

Design  Parallel groups

Centers  19

Geographical area  Europe

Sizes  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>510Change from Baseline in HbA1c (cardiovascular events)</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References